Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension
Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension
复制标题
DOI：
10.1161/01.hyp.35.1.501
复制
发表时间：
2000-01-01
期刊：
影响因子：
8.3
通讯作者：
Salvetti, A
中科院分区：
文献类型：
--
作者：
Ghiadoni, L;Virdis, A;Salvetti, A
原发性高血压患者的特征是基础和激动剂诱发的一氧化氮释放受损和内源性内皮素（ET）-1诱导的血管收缩增加。为了评估坎地沙坦（一种血管紧张素II 1型受体阻滞剂）是否能改善内皮功能，我们研究了15名高血压患者和15名对照受试者通过肱动脉内输注N-G-单甲基-L-精氨酸（L-NMMA）、去甲肾上腺素、ETA/B受体拮抗剂TAK 044、硝普钠和乙酰胆碱诱导的前臂血流（FBF）变化。在高血压患者中，在坎地沙坦酯（每日8 - 16 mg）治疗开始后2个月和12个月重复FBF研究。与对照组相比（最大FBF降低，-46+/-11%），高血压患者显示降低（P
Patients with essential hypertension are characterized by impaired basal and agonist-evoked nitric oxide release and increased endogenous endothelin (ET)-1-induced vasoconstriction. To assess whether candesartan, an angiotensin II type 1 receptor blocker, can improve endothelial function, we studied the changes in forearm blood flow (FBF) induced in 15 hypertensive patients and in 15 control subjects by the intrabrachial infusion of N-G-monomethyl-L-arginine (L-NMMA), norepinephrine, the ET A/B receptor antagonist TAK 044, sodium nitroprusside, and acetylcholine. In hypertensive patients, the FBF study was repeated 2 and 12 months after the start of treatment with candesartan cilexetil (8 to 16 mg daily). Compared with controls (maximal FBF decrease, -46+/-11%), hypertensive patients showed a reduced (P